Logo image of CTKB

CYTEK BIOSCIENCES INC (CTKB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CTKB - US23285D1090 - Common Stock

5.84 USD
-0.04 (-0.68%)
Last: 11/24/2025, 8:00:00 PM
5.84 USD
0 (0%)
After Hours: 11/24/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, CTKB scores 3 out of 10 in our fundamental rating. CTKB was compared to 58 industry peers in the Life Sciences Tools & Services industry. The financial health of CTKB is average, but there are quite some concerns on its profitability. CTKB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CTKB had negative earnings in the past year.
CTKB had a negative operating cash flow in the past year.
In multiple years CTKB reported negative net income over the last 5 years.
Of the past 5 years CTKB 4 years had a positive operating cash flow.
CTKB Yearly Net Income VS EBIT VS OCF VS FCFCTKB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -2.59%, CTKB is in line with its industry, outperforming 56.90% of the companies in the same industry.
The Return On Equity of CTKB (-3.39%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -2.59%
ROE -3.39%
ROIC N/A
ROA(3y)-1.05%
ROA(5y)-0.34%
ROE(3y)-1.33%
ROE(5y)-0.44%
ROIC(3y)N/A
ROIC(5y)N/A
CTKB Yearly ROA, ROE, ROICCTKB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

CTKB has a better Gross Margin (53.46%) than 65.52% of its industry peers.
In the last couple of years the Gross Margin of CTKB has grown nicely.
CTKB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.56%
GM growth 5Y2.26%
CTKB Yearly Profit, Operating, Gross MarginsCTKB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

CTKB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTKB has been reduced compared to 1 year ago.
CTKB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CTKB is higher compared to a year ago.
CTKB Yearly Shares OutstandingCTKB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CTKB Yearly Total Debt VS Total AssetsCTKB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

CTKB has an Altman-Z score of 4.66. This indicates that CTKB is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.66, CTKB is doing good in the industry, outperforming 79.31% of the companies in the same industry.
CTKB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CTKB (0.00) is better than 72.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.66
ROIC/WACCN/A
WACC10.06%
CTKB Yearly LT Debt VS Equity VS FCFCTKB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

CTKB has a Current Ratio of 5.17. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
CTKB's Current ratio of 5.17 is fine compared to the rest of the industry. CTKB outperforms 77.59% of its industry peers.
CTKB has a Quick Ratio of 4.48. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
CTKB has a Quick ratio of 4.48. This is in the better half of the industry: CTKB outperforms 79.31% of its industry peers.
Industry RankSector Rank
Current Ratio 5.17
Quick Ratio 4.48
CTKB Yearly Current Assets VS Current LiabilitesCTKB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CTKB have decreased strongly by -25.00% in the last year.
The Revenue has decreased by -2.18% in the past year.
Measured over the past years, CTKB shows a very strong growth in Revenue. The Revenue has been growing by 28.19% on average per year.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)-2.18%
Revenue growth 3Y16.13%
Revenue growth 5Y28.19%
Sales Q2Q%1.54%

3.2 Future

Based on estimates for the next years, CTKB will show a very negative growth in Earnings Per Share. The EPS will decrease by -46.25% on average per year.
The Revenue is expected to grow by 4.99% on average over the next years.
EPS Next Y-308%
EPS Next 2Y-92.95%
EPS Next 3Y-46.25%
EPS Next 5YN/A
Revenue Next Year-3.3%
Revenue Next 2Y1.84%
Revenue Next 3Y4.2%
Revenue Next 5Y4.99%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CTKB Yearly Revenue VS EstimatesCTKB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
CTKB Yearly EPS VS EstimatesCTKB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.1 -0.1 -0.2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CTKB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTKB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTKB Price Earnings VS Forward Price EarningsCTKB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTKB Per share dataCTKB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

CTKB's earnings are expected to decrease with -46.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-92.95%
EPS Next 3Y-46.25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTKB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTEK BIOSCIENCES INC

NASDAQ:CTKB (11/24/2025, 8:00:00 PM)

After market: 5.84 0 (0%)

5.84

-0.04 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)01-15 2026-01-15/amc
Inst Owners63.24%
Inst Owner Change0.84%
Ins Owners9.23%
Ins Owner Change2.5%
Market Cap746.70M
Revenue(TTM)196.83M
Net Income(TTM)-12.82M
Analysts78.18
Price Target5.36 (-8.22%)
Short Float %5.54%
Short Ratio5.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.64%
Min EPS beat(2)25.3%
Max EPS beat(2)43.98%
EPS beat(4)3
Avg EPS beat(4)1.29%
Min EPS beat(4)-96.08%
Max EPS beat(4)43.98%
EPS beat(8)5
Avg EPS beat(8)133.03%
EPS beat(12)6
Avg EPS beat(12)68.3%
EPS beat(16)10
Avg EPS beat(16)81.62%
Revenue beat(2)0
Avg Revenue beat(2)-1.98%
Min Revenue beat(2)-3.53%
Max Revenue beat(2)-0.43%
Revenue beat(4)0
Avg Revenue beat(4)-3.45%
Min Revenue beat(4)-5.11%
Max Revenue beat(4)-0.43%
Revenue beat(8)2
Avg Revenue beat(8)-2.52%
Revenue beat(12)3
Avg Revenue beat(12)-4.77%
Revenue beat(16)5
Avg Revenue beat(16)-3.49%
PT rev (1m)2.44%
PT rev (3m)-8.7%
EPS NQ rev (1m)-85.71%
EPS NQ rev (3m)-225%
EPS NY rev (1m)0%
EPS NY rev (3m)8.05%
Revenue NQ rev (1m)-0.63%
Revenue NQ rev (3m)-1.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.79
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 2.17
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS1.54
BVpS2.96
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.59%
ROE -3.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.46%
FCFM N/A
ROA(3y)-1.05%
ROA(5y)-0.34%
ROE(3y)-1.33%
ROE(5y)-0.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.56%
GM growth 5Y2.26%
F-ScoreN/A
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.2%
Cap/Sales 2.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.17
Quick Ratio 4.48
Altman-Z 4.66
F-ScoreN/A
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)175.97%
Cap/Depr(5y)227.57%
Cap/Sales(3y)3.46%
Cap/Sales(5y)3.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next Y-308%
EPS Next 2Y-92.95%
EPS Next 3Y-46.25%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.18%
Revenue growth 3Y16.13%
Revenue growth 5Y28.19%
Sales Q2Q%1.54%
Revenue Next Year-3.3%
Revenue Next 2Y1.84%
Revenue Next 3Y4.2%
Revenue Next 5Y4.99%
EBIT growth 1Y-34.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year127.51%
EBIT Next 3Y45.66%
EBIT Next 5Y33.94%
FCF growth 1Y24.52%
FCF growth 3Y331.22%
FCF growth 5YN/A
OCF growth 1Y-197.86%
OCF growth 3Y76.32%
OCF growth 5YN/A

CYTEK BIOSCIENCES INC / CTKB FAQ

What is the ChartMill fundamental rating of CYTEK BIOSCIENCES INC (CTKB) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTKB.


What is the valuation status of CYTEK BIOSCIENCES INC (CTKB) stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTEK BIOSCIENCES INC (CTKB). This can be considered as Overvalued.


How profitable is CYTEK BIOSCIENCES INC (CTKB) stock?

CYTEK BIOSCIENCES INC (CTKB) has a profitability rating of 2 / 10.


What is the financial health of CYTEK BIOSCIENCES INC (CTKB) stock?

The financial health rating of CYTEK BIOSCIENCES INC (CTKB) is 6 / 10.


What is the earnings growth outlook for CYTEK BIOSCIENCES INC?

The Earnings per Share (EPS) of CYTEK BIOSCIENCES INC (CTKB) is expected to decline by -308% in the next year.